한글목차

순환종양세포(CTC) 진단의 세계 시장은 2030년까지 238억 달러에 이를 전망

2023년에 114억 달러로 추정되는 순환종양세포(CTC) 진단 세계 시장은 분석 기간 2023-2030년에 CAGR 11.2%로 성장해 2030년에는 238억 달러에 달할 것으로 예측 . 이 보고서에서 분석한 부문 중 하나인 Detection & EnrichmentTechnology는 CAGR 10.8%로 성장을 지속하고, 분석 기간 종료 시 154억 달러에 도달할 것으로 예측됩니다. 분석기술 부문의 성장률은 분석 기간 동안 CAGR 12.7%로 추정됩니다.

미국 시장은 30억 달러로 추정, 중국은 CAGR 10.2%로 성장 예측

미국 순환종양세포(CTC) 진단 시장은 2023년 30억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 36억 달러 규모에 이를 것으로 예측되며, 분석 기간 2023-2030년의 CAGR은 10.2%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 10.0%와 9.4%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 7.8%로 성장할 것으로 예측됩니다.

세계 순환 종양 세포(CTC) 진단 시장 - 주요 동향과 촉진요인 요약

순환종양세포(CTC)는 치료전략의 개발을 이끌어 전이와 재발의 모니터링에 도움이 되는 주된 통찰력을 제공하며, 암의 진단과 관리를 진행하는데 있어서 매우 중요한 것이 되고 있습니다. 리퀴드 바이옵시로 알려진 혁신적인 접근법의 일환으로 CTC 진단은 암의 진행과 치료 효과를 비침습적으로 평가하여 종양 재발의 조기 발견을 촉진합니다. 이 접근법은 임상 혈액 샘플에서 CTC를 분리하고 분석하기 위해 바이오 마커를 통한 플랫폼과 첨단 생화학 기술을 포함한 다양한 기술을 활용합니다. 그러나 이러한 기술은 종종 종양 세포의 불균일성에 어려움을 겪고 검출 감도에 어려움을 겪습니다. 이러한 문제에도 불구하고 CTC의 열거와 분자 프로파일 링은 암 예후를 유의하게 예측할 수 있으며 환자의 결과를 개선하기 위해 고감도 CTC 검출 기술을 일상 임상 관리에 통합하는 것 중요성을 강조합니다.

최근 기술의 진보로 CTC를 분리하기 위한 보다 고감도로 바이오마커에 의존하지 않는 방법이 도입되어 암 예후의 정확성과 감도가 향상되고 있습니다. 주목할 만한 개발은 표면 하전 초상자성 나노프로브의 사용이며, 이는 바르부르크 효과와 관련된 생체전기 현상을 이용한 것으로, 암세포는 포도당 흡수와 젖산 분비의 상승에 의해 명확한 음전하 를 나타냅니다. 이 방법은 면역친화성 반응에 의존하고 CTC의 모든 하위집단, 특히 상피간엽전환(EMT)을 받는 CTC를 포획하지 못할 수 있는 종래 기술과는 대조적입니다. 밀도 기반 분리 및 마이크로플루이딕스 장치를 포함한 이러한 고급 접근법은 CTC 캡처의 특이성과 효율성을 향상시키고 정확성과 신뢰성이 가장 중요한 임상 환경에서 귀중합니다.

CTC 진단의 이용이 확대되고 있는 배경으로는 CTC 분석을 통해 확인된 개별 환자의 특징에 맞게 의료 치료를 조정하는 보다 광범위한 정밀의료 패러다임에 통합이 있습니다. 세계의 암 이환율이 상승함에 따라 CTC 진단과 같은 혁신적인 진단법이 시급해지고 있습니다. CTC 진단법은 환자에게 침습성이 낮은 옵션을 제공하고 전이의 조기 발견과 질병 진행의 모니터링을 용이하게 함으로써 암 관리에 큰 영향을 줄 수 있습니다. CTC 기술 개발에 있어서 학제간 협력, 컴퓨팅 생물학의 진보, 자금 조달 증가, 헬스케어 정책의 지원이 이러한 첨단 진단 도구의 채용을 더욱 촉진하고 있습니다. CTC 진단이 보다 임상에 통합되게 되면, 암 치료의 상황은 일변하고, 보다 개별화된, 효과적이고 시기 적절한 치료 전략으로 이어질 것으로 기대됩니다.

조사 대상 기업 예(총 48건)

• ApoCell, Inc.
• Biocep Ltd.
• Biocept, Inc.
• Biofluidica Microtechnologies LLC
• Celltraffix Inc.
• Clearbridge Biomedics
• Creatv Microtech, Inc.
• Cynvenio Biosystems, Inc.
• Fluxion Biosciences, Inc.
• Ikonisys, Inc.
• IVDiagnostics, Inc.
• Janssen Diagnostics LLC
• QIAGEN Hannover GmbH
• Rarecells Sas
• Screencell
• Stemcell Technologies, Inc.

목차

제1장 조사 방법

제2장 주요 요약

• 시장 개요
• 주요 기업
• 시장 동향과 촉진요인
• 세계 시장 전망

제3장 시장 분석

• 미국
• 캐나다
• 일본
• 중국
• 유럽
• 프랑스
• 독일
• 이탈리아
• 영국
• 기타 유럽
• 아시아태평양
• 세계 기타 지역

제4장 경쟁

영문목차

Global Circulating Tumor Cell (CTC) Diagnostics Market to Reach US$23.8 Billion by 2030

The global market for Circulating Tumor Cell (CTC) Diagnostics estimated at US$11.4 Billion in the year 2023, is expected to reach US$23.8 Billion by 2030, growing at a CAGR of 11.2% over the analysis period 2023-2030. Detection & EnrichmentTechnology, one of the segments analyzed in the report, is expected to record a 10.8% CAGR and reach US$15.4 Billion by the end of the analysis period. Growth in the Analysis Technology segment is estimated at 12.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.0 Billion While China is Forecast to Grow at 10.2% CAGR

The Circulating Tumor Cell (CTC) Diagnostics market in the U.S. is estimated at US$3.0 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$3.6 Billion by the year 2030 trailing a CAGR of 10.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.0% and 9.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.8% CAGR.

Global Circulating Tumor Cell (CTC) Diagnostics Market - Key Trends and Drivers Summarized

Circulating tumor cells (CTCs) have become crucial in advancing cancer diagnosis and management, providing key insights that guide the development of treatment strategies and help monitor metastasis and recurrence. As part of an innovative approach known as liquid biopsy, CTC diagnostics allow for the non-invasive evaluation of cancer progression and treatment effectiveness, facilitating the early detection of tumor recurrence. This approach leverages various technologies, including biomarker-mediated platforms and advanced biochemical methods, to isolate and analyze CTCs from clinical blood samples. These technologies, however, often struggle with the heterogeneity of tumor cells, which can lead to challenges in detection sensitivity. Despite these challenges, the enumeration and molecular profiling of CTCs can significantly predict cancer prognosis, underscoring the importance of integrating sensitive CTC detection technologies into routine clinical management to enhance patient outcomes.

Recent technological advancements have introduced more sensitive, biomarker-independent methods for isolating CTCs, enhancing the accuracy and sensitivity of cancer prognosis. A notable development is the use of surface-charged superparamagnetic nanoprobes, which capitalize on the bio-electrical phenomena associated with the Warburg effect, where cancer cells exhibit a distinct negative charge due to elevated glucose uptake and lactic acid secretion. This method contrasts with traditional techniques that rely on immuno-affinity reactions and can miss capturing all subpopulations of CTCs, particularly those undergoing epithelial-to-mesenchymal transition (EMT). These advanced approaches, including density-based separation and microfluidic devices, improve the specificity and efficiency of CTC capture, making them invaluable in clinical settings where precision and reliability are paramount.

The growing utilization of CTC diagnostics is driven by their integration into the broader paradigm of precision medicine, which tailors healthcare treatments to individual patient characteristics identified through CTC analysis. With the global rise in cancer incidence, there is a pressing need for innovative diagnostic methods like CTC diagnostics, which offer less invasive options for patients and can significantly impact cancer management by facilitating the early detection of metastasis and monitoring disease progression. Interdisciplinary collaboration in the development of CTC technologies, advancements in computational biology, increased funding, and supportive healthcare policies are further catalyzing the adoption of these advanced diagnostic tools. As CTC diagnostics become more integrated into clinical practice, they promise to transform the landscape of cancer treatment, leading to more personalized, effective, and timely therapeutic strategies.

Select Competitors (Total 48 Featured) -

• ApoCell, Inc.
• Biocep Ltd.
• Biocept, Inc.
• Biofluidica Microtechnologies LLC
• Celltraffix Inc.
• Clearbridge Biomedics
• Creatv Microtech, Inc.
• Cynvenio Biosystems, Inc.
• Fluxion Biosciences, Inc.
• Ikonisys, Inc.
• IVDiagnostics, Inc.
• Janssen Diagnostics LLC
• QIAGEN Hannover GmbH
• Rarecells Sas
• Screencell
• Stemcell Technologies, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Circulating Tumor Cell (CTC) Diagnostics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Incidence of Cancer Worldwide: Propels Growth in Circulating Tumor Cell (CTC) Diagnostics as a Vital Tool for Early Detection and Monitoring
  • Technological Advancements in CTC Isolation and Analysis Techniques: Drives Adoption of High-Performance Diagnostic Platforms
  • Rising Demand for Personalized Medicine: Throws the Spotlight On CTC Diagnostics for Tailored Treatment Strategies
  • Regulatory Shifts Towards Companion Diagnostics: Strengthens Business Case for CTC Testing in Treatment Decision-making
  • Growing Focus on Liquid Biopsy as a Non-invasive Diagnostic Tool: Expands Addressable Market Opportunity for CTC Testing
  • Growing Focus on Liquid Biopsy as a Non-invasive Diagnostic Tool: Expands Addressable Market Opportunity for CTC Testing
  • Emerging Applications of CTCs in Cancer Prognosis and Treatment Monitoring: Accelerates Demand for Comprehensive Diagnostic Solutions
  • Increasing Investments in Precision Oncology Research: Drives Adoption of CTC Technologies in Biomarker Discovery and Drug Development
  • Expansion of Point-of-Care Testing Capabilities: Propels Market Growth by Offering Rapid and Convenient CTC Analysis Solutions
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Circulating Tumor Cell (CTC) Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Detection & Enrichment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Detection & Enrichment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Detection & Enrichment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Direct Detection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Direct Detection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Direct Detection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Blood by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Bone Marrow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Bone Marrow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Bone Marrow by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Body Fluids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Body Fluids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Other Body Fluids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: World 16-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Clinical / Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Clinical / Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: World 16-Year Perspective for Clinical / Liquid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 29: USA Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: USA 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
  • TABLE 32: USA Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: USA 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: USA 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: Canada 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: Canada 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: Canada 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030
• JAPAN
  • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: Japan 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: Japan 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: Japan 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030
• CHINA
  • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 56: China Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: China Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: China 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
  • TABLE 59: China Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 61: China 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 64: China 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030
• EUROPE
  • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 65: Europe Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 66: Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 67: Europe 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 70: Europe 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 73: Europe 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 76: Europe 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030
• FRANCE
  • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 77: France Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 78: France Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 79: France 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
  • TABLE 80: France Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 82: France 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
  • TABLE 83: France Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 85: France 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030
• GERMANY
  • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 86: Germany Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Germany Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 88: Germany 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 91: Germany 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 94: Germany 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 95: Italy Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Italy Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 97: Italy 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 100: Italy 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 103: Italy 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 104: UK Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 105: UK Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 106: UK 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
  • TABLE 107: UK Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 109: UK 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
  • TABLE 110: UK Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 112: UK 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 113: Rest of Europe Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 114: Rest of Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 115: Rest of Europe 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
  • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 117: Rest of Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 118: Rest of Europe 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
  • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 120: Rest of Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 121: Rest of Europe 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Circulating Tumor Cell (CTC) Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 123: Asia-Pacific Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 124: Asia-Pacific 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
  • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 126: Asia-Pacific Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 127: Asia-Pacific 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
  • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 129: Asia-Pacific Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 130: Asia-Pacific 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030
• REST OF WORLD
  • TABLE 131: Rest of World Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 132: Rest of World Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Technology - Detection & Enrichment, Analysis and Direct Detection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 133: Rest of World 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Technology - Percentage Breakdown of Value Sales for Detection & Enrichment, Analysis and Direct Detection for the Years 2014, 2024 & 2030
  • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 135: Rest of World Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Blood, Bone Marrow and Other Body Fluids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 136: Rest of World 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Specimen - Percentage Breakdown of Value Sales for Blood, Bone Marrow and Other Body Fluids for the Years 2014, 2024 & 2030
  • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 138: Rest of World Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Application - Research and Clinical / Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 139: Rest of World 16-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Application - Percentage Breakdown of Value Sales for Research and Clinical / Liquid Biopsy for the Years 2014, 2024 & 2030

IV. COMPETITION